Abcam, ab258391, Human DDX60 knockout A549 cell lysate

Size: 1Kit
DDX60 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon13.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon13.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-DDX60, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DDX60 also known as DExD/H-box helicase 60 is a protein involved in antiviral responses. It has a molecular mass of approximately 180 kDa. DDX60 acts as an ATP-dependent RNA helicase unwinding RNA structures during viral replication processes. This protein is expressed mainly in immune-related tissues like the spleen and peripheral blood leukocytes indicating its role in immunity. Alternate names include DDX60L which denotes a related protein with similar functions.
Biological function summary
DDX60 plays an essential role in the detection of viral RNA acting as a sensor in the innate immune system. It forms part of a complex involved in recognizing and responding to viral infections. DDX60 interacts with other proteins like RIG-I a pivotal component in initiating antiviral signaling cascades. Through these interactions DDX60 facilitates the production of interferons which are key elements in mounting an effective immune response against viruses.
Pathways
DDX60 functions within the RIG-I-like receptor signaling pathway an important antiviral defense mechanism. This pathway includes proteins such as MAVS and IRF3 which work together to stimulate the expression of cytokines following pathogen recognition. DDX60's activity enhances the sensitivity of this pathway boosting the host's capacity to control viral replication and spread contributing to the overall immune response.
Variations in DDX60 expression have been linked to autoimmune conditions like systemic lupus erythematosus (SLE) and chronic viral infections such as hepatitis C. Abnormal regulation of this protein can lead to inappropriate immune activation or impaired response to infections. DDX60's association with RIG-I suggests its involvement in these diseases as both proteins are important in the body's effort to manage viral threats and the maintenance of immune homeostasis.